ES2722723T3 - Métodos para tratar enfermedades oculares asociadas con inflamación y proliferación vascular - Google Patents
Métodos para tratar enfermedades oculares asociadas con inflamación y proliferación vascular Download PDFInfo
- Publication number
- ES2722723T3 ES2722723T3 ES11843788T ES11843788T ES2722723T3 ES 2722723 T3 ES2722723 T3 ES 2722723T3 ES 11843788 T ES11843788 T ES 11843788T ES 11843788 T ES11843788 T ES 11843788T ES 2722723 T3 ES2722723 T3 ES 2722723T3
- Authority
- ES
- Spain
- Prior art keywords
- inflammation
- vascular proliferation
- methods
- diseases associated
- eye disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000030533 eye disease Diseases 0.000 title abstract 4
- 206010061218 Inflammation Diseases 0.000 title abstract 2
- 230000004054 inflammatory process Effects 0.000 title abstract 2
- 230000035755 proliferation Effects 0.000 title abstract 2
- 230000002792 vascular Effects 0.000 title abstract 2
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 2
- 208000002780 macular degeneration Diseases 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 208000002691 Choroiditis Diseases 0.000 abstract 1
- 206010010741 Conjunctivitis Diseases 0.000 abstract 1
- 206010011033 Corneal oedema Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 206010013774 Dry eye Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010022941 Iridocyclitis Diseases 0.000 abstract 1
- 208000001344 Macular Edema Diseases 0.000 abstract 1
- 206010025415 Macular oedema Diseases 0.000 abstract 1
- 208000003971 Posterior uveitis Diseases 0.000 abstract 1
- 201000002154 Pterygium Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 201000004612 anterior uveitis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000021921 corneal disease Diseases 0.000 abstract 1
- 201000004778 corneal edema Diseases 0.000 abstract 1
- 201000010230 macular retinal edema Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto de fórmula 4 **(Ver fórmula)** para ser usado en el tratamiento de una enfermedad ocular asociada con inflamación y/o proliferación vascular en un sujeto; en que la enfermedad ocular se selecciona entre el grupo que comprende retinopatía diabética, edema corneal, uveítis anterior y posterior, pterigión, enfermedades corneales, ojo seco, conjuntivitis, exudación inducida por alergia y láser, degeneración macular no relacionada con la edad, edema macular, degeneración macular relacionada con la edad y enfermedad ocular de von Hippel-Lindau; en la que p es un número entero entre 1 y 10; y R se selecciona entre el grupo que consiste en H y alquilo de C1 a C10; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2010905197A AU2010905197A0 (en) | 2010-11-24 | Methods of treating eye diseases associated with inflammation and vascular proliferation | |
| PCT/AU2011/001455 WO2012068612A1 (en) | 2010-11-24 | 2011-11-10 | Methods of treating eye diseases associated with inflammation and vascular proliferation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2722723T3 true ES2722723T3 (es) | 2019-08-16 |
Family
ID=46145280
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18207689T Active ES2829620T3 (es) | 2010-11-24 | 2011-11-10 | Procedimientos de tratamiento de enfermedades oculares asociadas con inflamación y proliferación vascular |
| ES11843788T Active ES2722723T3 (es) | 2010-11-24 | 2011-11-10 | Métodos para tratar enfermedades oculares asociadas con inflamación y proliferación vascular |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18207689T Active ES2829620T3 (es) | 2010-11-24 | 2011-11-10 | Procedimientos de tratamiento de enfermedades oculares asociadas con inflamación y proliferación vascular |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US9839640B2 (es) |
| EP (2) | EP3485883B1 (es) |
| JP (1) | JP5942131B2 (es) |
| KR (1) | KR101899613B1 (es) |
| CN (1) | CN103228275B (es) |
| AU (1) | AU2011334592C1 (es) |
| CA (1) | CA2815390C (es) |
| DK (2) | DK2642989T3 (es) |
| ES (2) | ES2829620T3 (es) |
| HR (1) | HRP20190561T1 (es) |
| HU (1) | HUE042676T2 (es) |
| MX (1) | MX352517B (es) |
| NZ (1) | NZ609144A (es) |
| PL (1) | PL2642989T3 (es) |
| PT (1) | PT2642989T (es) |
| RS (1) | RS58603B1 (es) |
| SG (1) | SG189326A1 (es) |
| SI (1) | SI2642989T1 (es) |
| TR (1) | TR201904760T4 (es) |
| WO (1) | WO2012068612A1 (es) |
| ZA (1) | ZA201302638B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101899613B1 (ko) | 2010-11-24 | 2018-09-17 | 오쿠렉스 피티와이 리미티드 | 염증 및 혈관 증식 관련 안 질환의 치료 방법 |
| KR20190115451A (ko) | 2017-02-03 | 2019-10-11 | 세르타 테라퓨틱스 피티와이 엘티디. | 항-섬유성 화합물 |
| CN110357789B (zh) * | 2018-04-11 | 2022-09-30 | 华东理工大学 | 作为dhodh抑制剂的n-取代丙烯酰胺衍生物及其制备和用途 |
| CA3185849A1 (en) * | 2020-06-05 | 2021-12-09 | Occurx Pty. Ltd. | Compounds and methods for the treatment of eye disorders |
| US20240174598A1 (en) * | 2021-03-17 | 2024-05-30 | Occurx Pty Ltd | Compounds for the treatment of disorders and salts and polymorphs thereof |
| US11905231B1 (en) * | 2023-01-31 | 2024-02-20 | Certa Therapeutics Pty Ltd | Solid forms, salts and polymorphs of anti-fibrotic compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09176003A (ja) * | 1995-12-28 | 1997-07-08 | Tsumura & Co | 角膜治療剤 |
| EA199800721A1 (ru) * | 1996-02-15 | 1999-02-25 | Киссеи Фармасьютикал Ко., Лтд. | Ингибитор реваскуляризации |
| JPH09278653A (ja) * | 1996-04-05 | 1997-10-28 | Santen Pharmaceut Co Ltd | 網膜疾患治療剤 |
| JPH10259129A (ja) * | 1997-01-16 | 1998-09-29 | Kissei Pharmaceut Co Ltd | 血管新生阻害剤 |
| EP0974352B1 (en) | 1997-02-14 | 2003-05-14 | Kissei Pharmaceutical Co., Ltd. | Drugs inhibiting progress of pterygium and postoperative recurrence of the same |
| JPH10330254A (ja) * | 1997-04-01 | 1998-12-15 | Kissei Pharmaceut Co Ltd | 翼状片の進行および術後の再発抑制剤 |
| US20070254055A1 (en) * | 2003-11-21 | 2007-11-01 | Trustees Of Tufts College | Therapeutic Avenanthramide Compounds |
| WO2006073126A1 (ja) | 2005-01-06 | 2006-07-13 | Kissei Pharmaceutical Co., Ltd. | 慢性移植片対宿主症におけるドライアイの予防および治療剤 |
| PT2035369E (pt) * | 2006-07-05 | 2014-09-30 | Fibrotech Therapeutics Pty Ltd | Compostos terapêuticos |
| WO2008131481A1 (en) * | 2007-04-26 | 2008-11-06 | Fibrotech Therapeutics Pty Ltd | Treatment of mesangioproliferative diseases |
| CA2690719A1 (en) * | 2007-07-06 | 2009-01-15 | Nuon Therapeutics, Inc. | Treatment of neuropathic pain |
| NZ584613A (en) | 2007-12-21 | 2011-07-29 | Fibrotech Therapeutics Pty Ltd | Halogenated cinnamoylbenzamide derivatives for anti-fibrotic drugs |
| US20100158905A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Combination therapy of arthritis with tranilast |
| WO2010144959A1 (en) | 2009-06-18 | 2010-12-23 | Fibrotech Therapeutics Pty Ltd | Analogues of anti-fibrotic agents |
| SG10201501272SA (en) | 2009-10-22 | 2015-04-29 | Fibrotech Therapeutics Pty Ltd | Fused ring analogues of anti-fibrotic agents |
| KR101899613B1 (ko) | 2010-11-24 | 2018-09-17 | 오쿠렉스 피티와이 리미티드 | 염증 및 혈관 증식 관련 안 질환의 치료 방법 |
-
2011
- 2011-11-10 KR KR1020137011658A patent/KR101899613B1/ko active Active
- 2011-11-10 US US13/989,677 patent/US9839640B2/en active Active
- 2011-11-10 PT PT11843788T patent/PT2642989T/pt unknown
- 2011-11-10 MX MX2013005561A patent/MX352517B/es active IP Right Grant
- 2011-11-10 TR TR2019/04760T patent/TR201904760T4/tr unknown
- 2011-11-10 NZ NZ609144A patent/NZ609144A/en unknown
- 2011-11-10 WO PCT/AU2011/001455 patent/WO2012068612A1/en active Application Filing
- 2011-11-10 ES ES18207689T patent/ES2829620T3/es active Active
- 2011-11-10 DK DK11843788.8T patent/DK2642989T3/en active
- 2011-11-10 CA CA2815390A patent/CA2815390C/en active Active
- 2011-11-10 ES ES11843788T patent/ES2722723T3/es active Active
- 2011-11-10 SG SG2013026406A patent/SG189326A1/en unknown
- 2011-11-10 PL PL11843788T patent/PL2642989T3/pl unknown
- 2011-11-10 JP JP2013540174A patent/JP5942131B2/ja active Active
- 2011-11-10 SI SI201131693T patent/SI2642989T1/sl unknown
- 2011-11-10 EP EP18207689.3A patent/EP3485883B1/en active Active
- 2011-11-10 AU AU2011334592A patent/AU2011334592C1/en active Active
- 2011-11-10 CN CN201180056738.4A patent/CN103228275B/zh active Active
- 2011-11-10 DK DK18207689.3T patent/DK3485883T3/da active
- 2011-11-10 RS RS20190411A patent/RS58603B1/sr unknown
- 2011-11-10 HU HUE11843788A patent/HUE042676T2/hu unknown
- 2011-11-10 EP EP11843788.8A patent/EP2642989B1/en active Active
-
2013
- 2013-04-12 ZA ZA2013/02638A patent/ZA201302638B/en unknown
-
2017
- 2017-11-08 US US15/807,166 patent/US10786510B2/en active Active
- 2017-11-08 US US15/807,235 patent/US20180117050A1/en not_active Abandoned
- 2017-11-08 US US15/807,282 patent/US10695353B2/en active Active - Reinstated
-
2019
- 2019-03-22 HR HRP20190561TT patent/HRP20190561T1/hr unknown
-
2020
- 2020-08-20 US US16/998,708 patent/US11583535B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016014634A (es) | Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. | |
| JOP20170147B1 (ar) | تركيبة عينية تشتمل على زيت الخروع ودهون ثلاثية متوسطة السلسلة | |
| BR112014008759A2 (pt) | tratamento de doença ocular | |
| ES2722723T3 (es) | Métodos para tratar enfermedades oculares asociadas con inflamación y proliferación vascular | |
| CO2019007810A2 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| EA201100654A1 (ru) | Соединения для лечения офтальмологических заболеваний и расстройств | |
| AR120961A2 (es) | Método y composición para tratar hipertensión ocular y glaucoma | |
| MX2017016344A (es) | Compuestos de benzoxacepina oxazolidinona y metodos de uso. | |
| NZ705624A (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| PH12015501942A1 (en) | Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders | |
| AR098693A1 (es) | Método para producir células del epitelio pigmentario retiniano (rpe) | |
| EA201490721A1 (ru) | Лекарственное средство для лечения заболеваний передней камеры глаза, включающее ребамипид и агент, удерживающий слезы | |
| MX2014002107A (es) | Sensibilizantes de (bacterio) clorofila para el tratamiento de enfermedades y transtornos oculares campo tecnico. | |
| EA201100462A1 (ru) | Серосвязанные соединения для лечения офтальмологических заболеваний и расстройств | |
| ECSP109870A (es) | Compuestos derivados de alquinil fenilo para tratar enfermedades y desórdenes oftálmicos | |
| EA201692402A1 (ru) | Лекарственные формы для местного применения и их использование | |
| AR062395A1 (es) | Uso de derivados del 2.5-dihidroxibenceno para el tratamiento de enfermedades oculares | |
| UY32829A (es) | Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo | |
| EA201691400A1 (ru) | Опсин-связывающие лиганды, композиции и способы их использования | |
| WO2017152129A3 (en) | Treatment of glaucoma and/or retinal diseases and formulations useful therefore | |
| EA201591594A1 (ru) | Модифицированный олигонуклеотид трф-бета для применения в способе предотвращения и/или лечения офтальмологического заболевания | |
| MX2019011925A (es) | Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. | |
| CL2011001812A1 (es) | Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras. | |
| NZ622403A (en) | Method for screening an agent being useful for the treatment of dry eye and/or corneal and conjunctival lesion and a pharmaceutical composition obtained by the method | |
| RU2010135224A (ru) | Способ хирургического лечения макулярного отека после факоэмульсификации катаракты |